184 related articles for article (PubMed ID: 11598248)
21. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
22. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
24. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases.
Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV
Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690
[TBL] [Abstract][Full Text] [Related]
25. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.
Wong CY; Gates VL; Tang B; Campbell J; Qing F; Lewandowski RJ; Thie J; Ho CL; Savin M; Salem R
Cancer Biother Radiopharm; 2010 Apr; 25(2):233-6. PubMed ID: 20423237
[TBL] [Abstract][Full Text] [Related]
26. [Diagnosis of colorectal cancer with FDG-PET].
Uno K
Nihon Rinsho; 2003 Sep; 61 Suppl 7():168-72. PubMed ID: 14574875
[No Abstract] [Full Text] [Related]
27. The clinical application of positron emission tomography to colorectal cancer management.
Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
[TBL] [Abstract][Full Text] [Related]
28. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
Tan MC; Castaldo ET; Gao F; Chari RS; Linehan DC; Wright JK; Hawkins WG; Siegel BA; Delbeke D; Pinson CW; Strasberg SM
J Am Coll Surg; 2008 May; 206(5):857-68; discussion 868-9. PubMed ID: 18471711
[TBL] [Abstract][Full Text] [Related]
29. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
30. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis.
Lake ES; Wadhwani S; Subar D; Kauser A; Harris C; Chang D; Lapsia S
Ann R Coll Surg Engl; 2014 Apr; 96(3):211-5. PubMed ID: 24780786
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET in colorectal cancer.
de Geus-Oei LF; Ruers TJ; Punt CJ; Leer JW; Corstens FH; Oyen WJ
Cancer Imaging; 2006 Oct; 6(Spec No A):S71-81. PubMed ID: 17114081
[TBL] [Abstract][Full Text] [Related]
33. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
34. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
[TBL] [Abstract][Full Text] [Related]
35. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
36. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease.
Rosa F; Meimarakis G; Stahl A; Bumm R; Hahn K; Tatsch K; Dresel S
Nuklearmedizin; 2004 Aug; 43(4):135-40. PubMed ID: 15316581
[TBL] [Abstract][Full Text] [Related]
37. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography for evaluation of colorectal carcinoma.
Vitola J; Delbeke D
Semin Roentgenol; 2002 Apr; 37(2):118-28. PubMed ID: 12134365
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET positive granuloma of the liver mimicking local recurrence after hepatic resection of colorectal liver metastasis.
Donadon M; Bona S; Montorsi M; Torzilli G
Hepatogastroenterology; 2010; 57(97):138-9. PubMed ID: 20422889
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.
Topal B; Flamen P; Aerts R; D'Hoore A; Filez L; Van Cutsem E; Mortelmans L; Penninckx F
Eur J Surg Oncol; 2001 Mar; 27(2):175-9. PubMed ID: 11345944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
